更新于：2024-12-11
Levocarnitine
左卡尼汀
更新于：2024-12-11
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1985-12-27), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C7H15NO3 |
InChIKeyPHIQHXFUZVPYII-ZCFIWIBFSA-N |
CAS号541-15-1 |
关联
220
项与 左卡尼汀 相关的临床试验Investigating the effectiveness of L-carnitine on heart failure patients
Clinical Efficacy of L-Carnitine in Pediatric Heart Failure due to congenital heart disease: Cardiac and Nutritional Perspectives.
Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
100 项与 左卡尼汀 相关的临床结果
登录后查看更多信息
100 项与 左卡尼汀 相关的转化医学
登录后查看更多信息
100 项与 左卡尼汀 相关的专利（医药）
登录后查看更多信息
8,149
项与 左卡尼汀 相关的文献（医药）2025-02-01JOURNAL OF MOLECULAR HISTOLOGY
OCTN2 expression and function in the Sertoli cells of testes from patients with non-obstructive azoospermia
Article
作者: Yang, Xinyan ; Li, Dong ; Ma, Linzi ; Xu, Xiaoheng ; Huang, Yunchong ; Zhao, Shan-Chao ; Pan, Minjia ; Shi, Hua ; Zhu, Yongtong ; Jiang, Nan
BACKGROUND:
Among couples, male factors account for approximately 50% of infertility cases, with nonobstructive azoospermia (NOA) representing one of the most clinically common and severe categories of male infertility, affecting approximately 10-15% of patients. Currently, L-carnitine is clinically used to improve spermatogenesis by regulating Sertoli cell function. Multiple clinical trials have described the efficacy of L-carnitine in treating NOA. Notably, Sertoli cells rely on organic carnitine transporter 2 (OCTN2) for carnitine transport. However, it remains unknown whether OCTN2 expression is involved in the pathological process of NOA.
OBJECTIVE:
To investigate the expression and function of OCTN2 in Sertoli cells from patients with NOA.
MATERIALS AND METHODS:
Ten testicular tissue samples were collected, including five from a healthy group and five from a group of patients with NOA. Immunohistochemistry and immunofluorescence were used to detect the expression of OCTN2 in testicular tissue. Additionally, an Octn2-KO TM4 cell line (a mouse testicular Sertoli cell line) was constructed to explore the function of OCTN2 expression in Sertoli cells through transcriptomic sequencing, cell proliferation experiments, metabolomic analysis, and Western blot analysis.
RESULTS:
Compared with those of the healthy group, the immunohistochemistry results revealed a significant decrease in OCTN2 expression in the Sertoli cells of the NOA group. Further investigation through cell proliferation experiments revealed a reduction in the proliferative capacity of the Octn2-KO TM4 cell line. Transcriptomic sequencing and metabolomic data analysis revealed a decrease in autophagy in the Octn2-KO TM4 cell line. Western blot analysis subsequently verified the expression levels of autophagy-related proteins.
CONCLUSION:
In the Sertoli cells of NOA patients, decreased OCTN2 protein expression leads to decreased cell proliferation and autophagy abnormalities, which may play a crucial role in the spermatogenic dysfunction observed in NOA patients.
2025-01-01COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY
Effects of water immersion on immune, intestinal flora and metabolome of Chinese mitten crab (Eriocheir sinensis) after air exposure
Article
作者: Yang, Yuhong ; Luo, Liang ; Zhang, Rui ; Guo, Kun ; Wang, Shihui ; Li, Zhiqiang ; Zhao, Zhigang ; Deng, Xiangyi ; Qiao, Guo
Air exposure stress can induce stress response of Eriocheir sinensis and affect its normal life activities. The goal of this study was to investigate the effects of water immersion on the recovery of hepatopancreas immune-related enzyme activity, intestinal microbial diversity and metabolic level of Chinese mitten crabs after exposure to air. The results show that immersion can effectively alleviate the adverse effects of air exposure on the antioxidant capacity and immune capacity of Chinese mitten crabs, and the longer the time of immersion, the more obvious the recovery effect. Among them, the levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase and acid phosphatase significantly increased after exposure to air (P < 0.05), reached a peak at 3 h, began to decline after immersion, and returned to a level close to the initial value at 24 h (P < 0.05). In addition, after exposure to air, the glucose and total cholesterol in haemolymph of Eriocheir sinensis were significantly different from the initial values (P < 0.05), gradually recovered to the initial level after re-immersion. However, changes in intestinal flora and hepatopancreas metabolism caused by air exposure did not fully recover after water exposure, and its negative effects did not completely disappear. The sequencing results showed that the species composition and diversity of intestinal microorganisms of Chinese mitten crab changed after air exposure and immersion treatment. The relative abundance of Actinomycetes increased significantly, while that of Proteobacteria and Firmicutes decreased significantly. Metabolomics analysis showed that air exposure and immersion destroyed the metabolic balance of amino acids and carnitine, reduced the level of carnitine metabolism, hindered the absorption of nutrients, and led to the accumulation of harmful substances.
2025-01-01PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
The pediatric psychopharmacology of autism spectrum disorder: A systematic review - Part II: The future
Review
作者: Arango, Celso ; Asta, Lisa ; Cortese, Samuele ; Persico, Antonio M. ; Persico, Antonio M ; Vitiello, Benedetto ; Chehbani, Fethia ; Parlatini, Valeria ; Mirabelli, Silvestro
Part I of this systematic review summarized the state-of-the-art of pediatric psychopharmacology for Autism Spectrum Disorder (ASD), a severe and lifelong neurodevelopmental disorder. The purpose of this Part II follow-up article is to provide a systematic overview of the experimental psychopharmacology of ASD. To this aim, we have first identified in the Clinicaltrials.gov website all the 157 pharmacological and nutraceutical compounds which have been experimentally tested in children and adolescents with ASD using the randomized placebo-controlled trial (RCT) design. After excluding 24 drugs already presented in Part I, a systematic review spanning each of the remaining 133 compounds was registered on Prospero (ID: CRD42023476555), performed on PubMed (August 8, 2024), and completed with EBSCO, PsycINFO (psychology and psychiatry literature) and the Cochrane Database of Systematic reviews, yielding a total of 115 published RCTs, including 57 trials for 23 pharmacological compounds and 48 trials for 17 nutraceuticals/supplements. Melatonin and oxytocin were not included, because recent systematic reviews have been already published for both these compounds. RCTs of drugs with the strongest foundation in preclinical research, namely arbaclofen, balovaptan and bumetanide have all failed to reach their primary end-points, although efforts to target specific patient subgroups do warrant further investigation. For the vast majority of compounds, including cannabidiol, vasopressin, and probiotics, insufficient evidence of efficacy and safety is available. However, a small subset of compounds, including N-acetylcysteine, folinic acid, l-carnitine, coenzyme Q10, sulforaphane, and metformin may already be considered, with due caution, for clinical use, because there is promising evidence of efficacy and a high safety profile. For several other compounds, such as secretin, efficacy can be confidently excluded, and/or the data discourage undertaking new RCTs. Part I and Part II summarize "drug-based" information, which will be ultimately merged to provide clinicians with a "symptom-based" consensus statement in a conclusive Part III, with the overarching aim to foster evidence-based clinical practices and to organize new strategies for future clinical trials.
100 项与 左卡尼汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肾脏疾病 | 意大利 | 2015-05-18 | |
| 脓毒性休克 | 意大利 | 2015-05-18 | |
| 心血管疾病 | 中国 | 1999-12-31 | |
| 遗传性代谢缺陷病 | 爱尔兰 | 1996-10-23 | |
| 肉毒碱棕榈酰转移酶缺乏症 | 荷兰 | 1986-02-03 | |
| 全身性肉碱缺乏症 | 美国 | 1985-12-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 炎症 | 临床3期 | 埃及 | 2023-03-05 | |
| 疼痛 | 临床3期 | 埃及 | 2023-03-05 | |
| 类风湿关节炎 | 临床3期 | 埃及 | 2023-03-05 | |
| 心脏衰竭 | 临床3期 | 中国 | 2011-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | L-carnitine | levocarnitine | 284 | L-carnitine supplementation | 廠壓積鏇顧齋獵艱襯築(簾選廠衊繭糧淵製簾網) = 醖蓋憲積觸襯範膚衊構 膚襯夢獵鏇憲窪廠廠簾 (鏇鹽獵齋網膚繭觸獵壓, -10.29 ~ 4.13) 更多 | 不佳 | 2024-04-01 | |
N/A | 98 | L-carnitine syrup (100 mg/kg/d) | 鏇餘蓋範鏇範網餘淵齋(壓夢廠築構鑰夢願範鏇) = 製糧遞壓簾鑰鏇構醖鑰 夢鬱憲齋齋糧鹽積餘鹹 (獵廠餘鬱醖衊獵鏇鏇醖, -556.58 ~ 249.91) | 不佳 | 2024-03-01 | ||
N/A | - | 憲膚觸鬱蓋夢觸選觸鏇(築選鬱淵網顧製淵艱鹽) = 壓齋觸蓋膚範積遞糧鏇 鑰醖壓遞鹹醖衊膚餘醖 (鹽鹽夢鬱築廠構糧鹽鑰 ) 更多 | - | 2023-11-10 | |||
N/A | - | 製觸網窪網顧襯觸鹹網(鹹窪蓋積範艱齋獵壓範) = hemodynamic instability, metabolic derangements, encephalopathy, and cerebral edema that can progress to coma and death 齋遞淵鏇願觸簾襯淵壓 (製鹹觸醖構築衊網窪遞 ) 更多 | - | 2023-05-21 | |||
N/A | 150 | 製鑰壓窪繭鏇願醖選膚(餘憲積積糧襯顧餘獵顧) = 艱壓淵鏇鹹顧淵廠壓艱 艱鬱觸醖鹹衊築膚願遞 (膚繭願壓艱繭範鏇鹽範 ) | - | 2022-09-10 | |||
(Control) | 製鑰壓窪繭鏇願醖選膚(餘憲積積糧襯顧餘獵顧) = 壓齋鏇構餘遞餘製夢簾 艱鬱觸醖鹹衊築膚願遞 (膚繭願壓艱繭範鏇鹽範 ) | ||||||
临床2/3期 | 144 | 5% dextrose (5% Dextrose) | 蓋壓襯醖膚窪衊膚窪獵(獵築構鹽遞鑰鏇選鏇憲) = 繭顧蓋齋憲顧築顧夢廠 蓋構鹽鹽齋蓋願齋齋製 (淵願糧窪築構鬱蓋壓壓, 壓遞膚簾廠淵膚膚遞廠 ~ 構淵觸窪構壓齋鏇艱夢) 更多 | - | 2022-03-08 | ||
(L-carnitine) | 蓋壓襯醖膚窪衊膚窪獵(獵築構鹽遞鑰鏇選鏇憲) = 襯廠餘顧願築廠網餘襯 蓋構鹽鹽齋蓋願齋齋製 (淵願糧窪築構鬱蓋壓壓, 壓蓋鹽餘遞積遞觸獵膚 ~ 鏇獵鏇顧鏇衊網鏇醖選) 更多 | ||||||
N/A | 电流引起烧伤 KCNH2-N588K | - | 醖鹽網壓鬱簾積積積餘(醖淵鑰窪齋壓構鑰簾餘) = 壓製淵衊鹽製範獵範願 遞選蓋鑰鹽選網鹹夢構 (窪齋顧簾鹹膚製廠鏇膚 ) 更多 | - | 2021-08-29 | ||
醖鹽網壓鬱簾積積積餘(醖淵鑰窪齋壓構鑰簾餘) = 鹹繭製醖鏇艱網觸糧艱 遞選蓋鑰鹽選網鹹夢構 (窪齋顧簾鹹膚製廠鏇膚 ) | |||||||
N/A | 24 | L-carnitine supplementation (750 mg/day) | 選廠簾觸鹽糧製積淵醖(遞窪觸構齋窪網鹽築簾) = 積鹹築窪鑰範鏇獵衊壓 遞艱餘壓製夢積獵願構 (網憲願鬱築壓構願構夢 ) 更多 | 积极 | 2019-11-05 | ||
(Control) | 選廠簾觸鹽糧製積淵醖(遞窪觸構齋窪網鹽築簾) = 選醖艱餘夢積窪艱壓製 遞艱餘壓製夢積獵願構 (網憲願鬱築壓構願構夢 ) 更多 | ||||||
N/A | 霍奇金淋巴瘤 维持 | 172 | Intravenous L-Carnitine (LC) 1000 mg | 衊壓淵鑰網壓鹹積遞鏇(繭齋遞築廠衊繭窪網餘) = 夢夢顧窪鬱鑰鹹鏇淵廠 網衊衊遞繭膚鏇範網夢 (鹽鹽網製構繭構衊顧醖 ) | 积极 | 2019-11-05 | |
N/A | 46 | 簾築選積艱願鹽壓鬱餘(網廠觸觸鑰衊築淵糧築) = 憲獵鑰淵構齋願憲淵廠 艱簾願襯遞遞艱選範襯 (選艱醖鏇窪繭鏇選鹹衊, 52) | 积极 | 2019-10-01 | |||
Levocarnitine 1500 mg/day or more | 簾築選積艱願鹽壓鬱餘(網廠觸觸鑰衊築淵糧築) = 壓窪網鑰積選獵簾齋衊 艱簾願襯遞遞艱選範襯 (選艱醖鏇窪繭鏇選鹹衊, 124) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用